Valneva Initiates Second Phase 2 Study for its Lyme Disease Vaccine Candidate VLA15

Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15.

Read more